Accounts payable and accrued expenses, including 466 and 19 to related parties as of june 30, 2025 and december 31, 2024, respectively
7,572
Lease liability, short term
15
Dividends payable
115
Derivative liability
105,498
Total current liabilities
113,200
Total liabilities
113,200
Accumulated deficit
-278,529
Common stock, 0.001 par value, authorized 200,000,000 shares, 30,793,135 and 17,239,096 issued and outstanding as of june 30, 2025 and december 31, 2024, respectively
31
Additional paid-in-capital
273,343
Accumulated other comprehensive income
1,538
Total stockholders deficit attributable to biosig technologies, inc
-3,617
Non-controlling interest
33
Total stockholders deficit
-3,584
Redeemable series c 9 convertible preferred stock, 0.001 par value, 1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding (liquidation preference of 105 cumulative dividends payable of 115 and 110 as of june 30, 2025 and december 31, 2024, respectively)
105
Total liabilities, mezzanine equity and stockholders deficit
109,721
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.